励晶太平洋(00575.HK)战略合作伙伴提交治疗早泄新药申请

阿斯达克财经2024-12-19

励晶太平洋(00575.HK) 宣布，商业战略合作伙伴江苏万邦医药已于前日(17日)向国家药监局提交新药申请注册档案，并预计自提交日期起12个月内获批。江苏万邦医药须负责自费从国家药品监督管理局获得新药申请并维持在中国进口Senstend所需的任何及所有监管批准。此外，重要的是，江苏万邦医药全权负责Senstend在中国的市场营销、销售及分销，并与制造商联络以采购及供应Senstend，以实现其...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492219304?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210705170236892_s.jpg","is_english":false,"pubTime":"2024-12-19 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492219304","market":"sh","top_or_hot":-1,"title":"励晶太平洋(00575.HK)战略合作伙伴提交治疗早泄新药申请","media":"阿斯达克财经","content":"<html><body><div>\n<p>励晶太平洋(00575.HK) 宣布，商业战略合作伙伴江苏万邦医药已于前日(17日)向国家药监局提交新药申请注册档案，并预计自提交日期起12个月内获批。江苏万邦医药须负责自费从国家药品监督管理局获得新药申请并维持在中国进口Senstend所需的任何及所有监管批准。此外，重要的是，江苏万邦医药全权负责Senstend在中国的市场营销、销售及分销，并与制造商联络以采购及供应Senstend，以实现其...</p>\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405155/latest-news/AAFN\">网页链接</a>\n</div>\n</body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>励晶太平洋(00575.HK)战略合作伙伴提交治疗早泄新药申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n励晶太平洋(00575.HK)战略合作伙伴提交治疗早泄新药申请\n</h2>\n<h4 class=\"meta\">\n\n\n2024-12-19 09:44 北京时间   <a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405155/latest-news/AAFN\"><strong>阿斯达克财经</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>励晶太平洋(00575.HK) 宣布，商业战略合作伙伴江苏万邦医药已于前日(17日)向国家药监局提交新药申请注册档案，并预计自提交日期起12个月内获批。江苏万邦医药须负责自费从国家药品监督管理局获得新药申请并维持在中国进口Senstend所需的任何及所有监管批准。此外，重要的是，江苏万邦医药全权负责Senstend在中国的市场营销、销售及分销，并与制造商联络以采购及供应Senstend，以实现其...</p>\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405155/latest-news/AAFN\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00575","symbol_name":"励晶太平洋","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405155/latest-news/AAFN","article_id":"2492219304","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210705170236892_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492219304","pubTimestamp":1734572640,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"励晶太平洋(00575.HK) 宣布，商业战略合作伙伴江苏万邦医药已于前日(17日)向国家药监局提交新药申请注册档案，并预计自提交日期起12个月内获批。江苏万邦医药须负责自费从国家药品监督管理局获得新药申请并维持在中国进口Senstend所需的任何及所有监管批准。此外，重要的是，江苏万邦医药全权负责Senstend在中国的市场营销、销售及分销，并与制造商联络以采购及供应Senstend，以实现其销售目标。Senstend乃两种上市药物利多卡因及丙胺卡因的专有配方，透过为治疗早泄而开发的计量气雾剂分配。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00575":"励晶太平洋"},"translate_title":"Regent Pacific (00575. HK) strategic partner submits new drug application for the treatment of premature ejaculation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00575":1},"content_text":"励晶太平洋(00575.HK) 宣布，商业战略合作伙伴江苏万邦医药已于前日(17日)向国家药监局提交新药申请注册档案，并预计自提交日期起12个月内获批。江苏万邦医药须负责自费从国家药品监督管理局获得新药申请并维持在中国进口Senstend所需的任何及所有监管批准。此外，重要的是，江苏万邦医药全权负责Senstend在中国的市场营销、销售及分销，并与制造商联络以采购及供应Senstend，以实现其销售目标。Senstend乃两种上市药物利多卡因及丙胺卡因的专有配方，透过为治疗早泄而开发的计量气雾剂分配。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.5","shortVersion":"4.31.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492219304"}